Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523980 | 0.88 | REN (0.51) | REN | |
| SCHEMBL17013293 | 0.88 | REN (0.43) | REN | |
| SCHEMBL16459439 | 0.84 | REN (0.40) | REN | |
| SCHEMBL12524620 | 0.83 | REN (0.52) | REN | |
| SCHEMBL78153 | 0.83 | REN (0.55) | RENSLC22A12 | |
| SCHEMBL16471692 | 0.82 | REN (0.51) | REN | |
| SCHEMBL12524619 | 0.81 | REN (0.53) | REN | |
| SCHEMBL16471683 | 0.80 | REN (0.51) | REN | |
| SCHEMBL16471691 | 0.80 | REN (0.50) | REN | |
| SCHEMBL16471679 | 0.79 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| EP-2687518-B1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-11-01 | — | — | EP | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| EP-2687518-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| WO-2012124775-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | REN 1/4885SLC22A12 959/4885 |
| US-10155731-B2 | Nitrogen-containing saturated heterocyclic compound | REN, AGTR1, AGTR2 | REN 1/4885SLC22A12 959/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | REN 1/4885SLC22A12 943/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | REN 1/4885SLC22A12 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.